89bio, Inc. ETNB
At closeOct 30, 2025, 4:00 PM EDT
52-week range unavailable
- YTD
- +89.77%
- 1 year
- +85.73%
- Market cap
- 2.20B
- Shares out
- 148.49M
- YTD return
- +89.77%
- 1-year return
- +85.73%
- Volume
- 38.51M
- Open
- 14.84
- Previous close
- 14.84
- Day's range
- 14.84 – 14.84
- Analysts
- Buy
- Price target
- 30.38 (+104.7%)
2Y +4.67 (+45.92%)
Key statistics
- Enterprise value
- 1.68B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -257.73M
- Total cash
- 561.16M
- Total debt
- 37.62M
- Return on equity
- -86.86%
- Short % of float
- 6.30%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: buy
- Target (low)
- 14.50
- Target (mean)
- 30.38
- Target (high)
- 55.00
- Strong buy0
- Buy2
- Hold4
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2025 | Sep 30, 2025 | -0.50 | -1.39 | -0.89 | -178.00% |
| Aug 7, 2025 | Jun 30, 2025 | -0.49 | -0.71 | -0.22 | -44.90% |
| May 1, 2025 | Mar 31, 2025 | -0.50 | -0.49 | +0.01 | +2.00% |
| Feb 27, 2025 | Dec 31, 2024 | -0.60 | -1.02 | -0.42 | -70.00% |
| Nov 7, 2024 | Sep 30, 2024 | -0.64 | -1.39 | -0.75 | -117.19% |
| Aug 5, 2024 | Jun 30, 2024 | -0.57 | -0.48 | +0.09 | +15.79% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 19, 2025 | Raymond James | down | Outperform | Market Perform |
| Sep 19, 2025 | Wolfe Research | down | Outperform | Peer Perform |
| Sep 19, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 25, 2025 | B of A Securities | main | Buy | Buy |
| Aug 8, 2025 | RBC Capital | main | Sector Perform | Sector Perform |
| Mar 14, 2025 | Goldman Sachs | init | — | Neutral |
About 89bio, Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as The company was founded in 2018 and is based in San Francisco, California. As of October 29, 2025, 89bio, Inc. operates as a subsidiary of Roche Holding AG.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- 89bio.com
News
Deal Dispatch: Need M&A Approval? FCC Chair Explains How To Get It 
Russell 2000 Hits All-Time Highs: 8 Stocks Power Small-Cap Comeback 
12 Health Care Stocks Moving In Thursday's Intraday Session 
Gold Falls Over 1%; Darden Posts Downbeat Earnings 
Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday 
Nasdaq Surges 100 Points; Bionano Genomics Shares Plunge 
Stock Market Today: S&P 500, Nasdaq Futures Rise Following Fed Rate Cuts— Nvidia And Intel In Focus After $5 Billion Investment Deal (UPDATED) 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
Why Bullish Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket 
Why Vertiv Holdings Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on ETNB — it syncs with the Stock Master app.